Gene expression changes underlying prostate cancer metastasis
Prostate cancer is one of the most common cancers among men. The American Cancer Society estimates that there will be 220,800 new cases of prostate cancer in 2015 and 27,540 prostate cancer related deaths. The National Cancer Institute’s SEER database shows that the 5-year survival rate for metastatic prostate cancer is only 28%. Cancer metastasis – the spread of cancer from a primary tumor to sites throughout the body – is the most important rate limiting step leading to death. The hallmarks of metastasis are primary tumor invasiveness, the acquisition of a vascular blood supply (tumor angiogenesis), and tumor cell invasion and growth at the distant site. Understanding how tumor cells become invasive is fundamentally important to developing strategies to stop that process.
A protein called hepatocyte growth factor (HGF) is a critical regulator of invasiveness in many cancers, including prostate cancer. In fact, most growth factors regulate other cell activities besides growth, such as cellular metabolism and migration, but are named on the basis of how they were originally discovered; this multiplicity of action is called pleitropism. HGF regulates cell proliferation, but also regulates migration, invasiveness and even angiogenesis, making the subversion of HGF activity in cancer dangerous in many respects. However, HGF is also important in promoting survival, immunity and repair in normal tissues, so blocking all HGF activity throughout the body as an anti-cancer strategy is a compromise. Blocking only the harmful HGF effects while maintaining its positive attributes could potentially block tumor metastasis while maintaining systemic health; to reach this ideal we have to understand the molecular basis of HGF pleiotropism. Remarkably, the nature of HGF itself affords a unique opportunity to just that: the HGF gene encodes five distinct protein isoforms and one, known as NK2, is special in that it drives only cell motility and invasion, but not cell proliferation.
Cecchi et al. exploited this difference in biological activity by performing a global comparison of gene expression changes driven by HGF and NK2 in a prostate cancer cell line which, when implanted into mice, mimics the process of primary tumor growth and robust metastatic spread. Gene expression changes were identified using arrays that contain ~54,000 probes to follow ~30,000 genes. Analysis of 36 such arrays covering multiple time points for each HGF isoform, a total of ~1.9 million measurements, ultimately revealed 345 genes whose expression change distinguished motility and invasion from other HGF biological effects. Many of these expression changes occurred in genes with known or suspected roles in controlling motility or invasion, and some were recognized contributors to prostate cancer progression. Cecchi et al. then compared this gene set with those gathered from patient samples analyzed as part of The Cancer Genome Atlas project of the National Institutes of Health. They found that 24 of the 345 HGF-driven, invasion-associated gene expression changes which also occurred in a collective majority of 85 prostate cancer cases had significant impact on patient survival. Of the 24, only 1 gene expression change was associated with prolonged survival, whereas 23 were associated with significantly decreased disease-free patient survival. Moreover, these 23 changes also co-occurred in the same patients with strikingly high frequency. These findings support the likelihood that “master switches” controlling these gene expression changes such as HGF are critical drivers of prostate cancer metastasis and provide guidance for the development of better diagnostics and therapeutics for this important disease.
Expression array analysis of the hepatocyte growth factor invasive program.
Cecchi F, Lih CJ, Lee YH, Walsh W, Rabe DC, Williams PM, Bottaro DP
Clin Exp Metastasis. 2015 Oct;32(7)
|Melanoma is controlling metastasis of melanoma… The title is provocative, because most will most ask: but who other than mm can control the metastasis of melanoma? But let's get on the path of facts and procedures…|
|MTA3: A master coregulator of physiology and oncogenesis The discovery of novel therapeutics for treatment of cancer is today’s prime concern due to abundantly increasing cancer drug resistance and deaths worldwide. MTA3, a member of metastasis-associated protein (MTA)…|
|Cyagen Biosciences – Helping you choose the right… While many animal models are available “ off the shelf ” through various repositories and collaborations, generation of novel animal models has allowed for more effective studies, not limited by…|
|Adapting sperm RNA as a fertility diagnostic for the male Infertility is a global public health issue affecting about 13 percent of couples of reproductive age. After one year of unprotected intercourse, couples having difficulties to conceive often seek reproductive…|
|The challenge and impact of engaging hard-to-reach… Men from hard-to-reach populations frequently report poor health statistics and have therefore been highlighted as a particular area of concern for men’s health practitioners and professionals.It has been argued that…|
|Undertreatment of men in their seventies with… Prostate cancer may be cured by either surgery or radiation treatment, but these “radical treatments” often cause permanent side effects that negatively affect the quality of life. Small prostate cancers…|